Physician profile
Amy Todd
NPI 1427635838
$903.10
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $182 · 2023: $363 · 2024: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $178.44 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $168.58 | 2021-2024 | Farxiga, Breztri |
| Pfizer INC. | $116.60 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $75.73 | 2022-2024 | Austedo Xr |
| Novo Nordisk INC | $60.00 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $51.01 | 2023-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.98 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $36.97 | 2022-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.80 | 2022-2023 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $24.04 | 2022 | |
| Neurelis, INC. | $22.34 | 2023 | Valtoco |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.95 | 2024 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $20.05 | 2021 | |
| Merck Sharp & Dohme LLC | $19.05 | 2021 | |
| Medicomp INC | $15.56 | 2023 | Telepatch Cardiac Monitor |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.